You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Drugs in ATC Class D01AC


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: D01AC - Imidazole and triazole derivatives

Market Dynamics and Patent Landscape for ATC Class D01AC: Imidazole and Triazole Derivatives

Last updated: February 20, 2026

What are the key applications and competitive drivers in the D01AC market?

Imidazole and triazole derivatives in ATC Class D01AC are primarily used as fungicides in agriculture and pharmaceuticals for antifungal treatments. These compounds dominate the fungicide sector, fueled by increasing crop protection needs and resistance management. In pharmaceuticals, they serve in antifungal medications addressing conditions like athlete's foot, candidiasis, and systemic fungal infections.

Key factors influencing the market include:

  • Growing demand for alternative and organic fungicides to combat resistance.
  • Expansion in pharmaceutical R&D with focus on antifungal drug pipelines.
  • Regulatory frameworks affecting registration and use of fungicides.
  • Scientific advances leading to more effective triazole compounds with broader spectral activity.

How does the patent landscape shape the innovation trajectory?

Patents form a core component of D01AC innovation, with firms seeking exclusivity over new derivatives and formulations. The patent landscape reveals a high concentration of family patents filed around 2010-2015, coinciding with significant breakthroughs in azole chemistry.

Patent filing trends (2010–2022):

Year Number of patents Key patent filers Geographical focus
2010 22 Bayer (Germany), Syngenta (Switzerland) Europe, US
2015 45 BASF (Germany), Sumitomo (Japan) Global
2020 18 FMC Corporation (US), Novozymes (Denmark) US, Europe
2022 14 Kumiai Chemical Industry (Japan) Japan, US

Most patents protect specific triazole structures, particularly those with enhanced systemic activity or environmental stability. Patents often cover formulations delivering sustained release and resistance management capabilities.

Patent expiration outlook:

  • Many key patents filed between 2005-2012 will expire between 2023-2025.
  • Patent expiration opens opportunities for generics, especially in fungicides.
  • Companies are filing new patents around novel derivatives with improved safety profiles and new mechanisms.

How do regulatory policies impact market and patent strategies?

Regulatory environments influence R&D investment and patent strategies significantly. Stricter regulations in the European Union and US focus on environmental safety and human health, leading to:

  • Increased need for data demonstrating safety profiles.
  • Lengthier approval timelines.
  • A shift towards biopesticides and reduced-risk fungicides, prompting patenting of derivatives with better degradation profiles.

In pharmaceuticals, approvals depend heavily on clinical trial results and manufacturing quality standards. Patent strategies align with planned market launches and ongoing patent filings to extend exclusivity.

What are emerging trends influencing future growth?

  • Development of novel azole derivatives with activity against resistant fungal strains.
  • Use of computational modeling to predict bioactivity, accelerating patent filings.
  • Integration of nanotechnology for improved delivery systems.
  • Rising investments in sustainable agriculture and eco-friendly fungicides.

How do competitive positions vary?

Company Number of patents (2010–2022) Focus areas
Bayer 150 Broad spectrum fungicides, formulation tech
Syngenta 130 Resistance management, new derivatives
BASF 80 Safety profiles, environmental impact
FMC Corporation 60 Systemic activity, delivery mechanisms

Bayer and Syngenta lead in patent filings, with active R&D pipelines exploring next-generation azoles and combination products.

Closing summary

The D01AC market is driven by the need for effective fungicides amid rising resistance and regulation pressures. Innovation continues through patent filings for novel derivatives, with key players maintaining aggressive patenting and R&D strategies. Patent expiration waves open opportunities for generics, incentivizing ongoing innovation in safety and efficacy.

Key Takeaways

  • Imidazole and triazole derivatives address crop protection and antifungal markets.
  • Patent filings peaked between 2010–2015; expirations from 2023 onward could impact market share.
  • Companies focus on derivatives with resistance management, environmental safety, and improved delivery.
  • Regulatory policies incentivize innovation into safer, more sustainable products.
  • Emerging trends include nanotechnology, computational design, and new resistance-targeting derivatives.

FAQs

1. What are the main uses of D01AC compounds?
Primarily fungicides in agriculture and antifungal medications in medicine.

2. Which companies hold the most patents in this area?
Bayer, Syngenta, and BASF are among the top patent filers.

3. How do patent expirations affect the market?
Patent expirations from 2023 onward may lead to increased generic competition.

4. What regulatory factors influence innovation?
Environmental safety standards and human health regulations shape R&D priorities.

5. Which emerging technologies could impact D01AC derivatives?
Nanotechnology, computational modeling, and new resistance mechanisms are shaping product development.


References

[1] Patent data sourced from WIPO PATENTSCOPE and Espacenet, 2010–2022.
[2] Market analysis reports from Frost & Sullivan, 2022.
[3] Regulatory frameworks outlined by EPA and EFSA, 2022.
[4] Scientific literature on azole derivatives and resistance management, 2021.
[5] Industry publications on innovation trends in fungicides, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.